Pittet

Home

About

Mikael Pittet’s Lab

My laboratory performs a research program on the host immune response in vivo with the main goal to offer valuable new ways to combat cancer. We use various modalities, including in vivo imaging, to study where, when and how immune cells are produced, traffic, and mediate regulatory or effector functions. The studies make use of both genetic mouse models, which allow manipulations and analyses of mechanisms and causality, and human patient material, to ensure that the results are anchored in clinical correlates. This dual approach gives opportunities for discovery of novel contributions of the immune response to tumor progression, new biomarkers useful for diagnosis and prognosis, and novel targets for therapeutic intervention. Dr. Pittet directs Cancer Immunology Program at CSB and collaborates with several immunology programs at Harvard Medical School, Massachusetts General Hospital and Massachusetts Institute of Technology.

In vivo imaging of immune cells at different scales.
Imaging modalities include single photon emission computed
tomography – X-ray computed tomography (SPECT-CT), fluorescence
mediated tomography (FMT), microscopic fiber optics, and intravital
multiphoton microscopy (IVM).

Recent Publications (more...)

Hoyer FF, Naxerova K, Schloss MJ, Hulsmans M, Nair AV, Dutta P, Calcagno DM, Herisson F, Anzai A, Sun Y, Wojtkiewicz G, Rohde D, Frodermann V, Vandoorne K, Courties G, Iwamoto Y, Garris CS, Williams DL, Breton S, Brown D, Whalen M, Libby P, Pittet MJ, King KR, Weissleder R, Swirski FK, Nahrendorf M
Tissue-Specific Macrophage Responses to Remote Injury Impact the Outcome of Subsequent Local Immune Challenge.
Immunity. 2019;51(5):899-914.e7 - PMID: 31732166 - PMCID: PMC6892583 - DOI: 10.1016/j.immuni.2019.10.010
Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R
Development of adamantane-conjugated TLR7/8 agonists for supramolecular delivery and cancer immunotherapy
Theranostics. 2019;:ePub
Zilionis R*, Engblom C*, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, Krishnan I, Maroni G, Meyerovitz CV, Kerwin CM, Choi S, Richards WG, De Rienzo A, Tenen DG, Bueno R, Levantini E, Pittet MJ**, Klein AM**
Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species.
Immunity. 2019;50(5):1317-1334.e10 - PMID: 30979687 - PMCID: PMC6620049 - DOI: 10.1016/j.immuni.2019.03.009
Liao HW, Garris C, Pfirschke C, Rickelt S, Arlauckas S, Siwicki M, Kohler RH, Weissleder R, Sundvold-Gjerstad V, Sveinbjørnsson B, Rekdal Ø, Pittet MJ
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects.
Cell Stress. 2019;3(11):348-360 - PMID: 31799501 - PMCID: PMC6859426 - DOI: 10.15698/cst2019.11.204

Recent News (more...)

2019-04-18: Congratulations to Jeremy Gungabeesoon (Pittet lab) for becoming a 2019 Landry Cancer Biology Fellow at Harvard University. This is a big honor!
2019-04-16: "Discovering Myeloid Cells in Lung Tumors" - Our work from the Pittet lab and Klein lab is out! See also interview with the authors.
2018-12-26: Five CSB PIs are on the list of Highly Cited Researchers of 2018. Congratulations to Brad Bernstein, Matthias Nahrendorf, Mikael Pittet, Fil Swirski, and Ralph Weissleder!
2018-12-11: “A small population of immune cells is key for successful cancer immunotherapy” - Study by Garris et al. from the Pittet Lab. See also interview with the authors.
2018-10-02: The Cover of Science Immunology's September issue features our hand-drawn sketch of a microscopy room used for intravital imaging and discussed in this review.